Brand Institute, a company involved in pharmaceutical and healthcare-related name development, announced on Friday that it has worked with United Kingdom-based Myovant Sciences for the development of the brand name ORGOVYX (relugolix), for an oral medication intended to treat adult patients with advanced hormone-sensitive prostate cancer.
Myovant Sciences developed the product, which it said is the first and only oral androgen deprivation therapy offered in Europe intended to treat advanced hormone-sensitive prostate cancer.
The European Commission (EC) has granted marketing authorisation for the product in all member states of the European Union, Iceland, Lichtenstein, and Norway. The product received US Food and Drug Administration (FDA) approval to treat adult patients with advanced prostate cancer in December 2020.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories